Procter & Gamble (PGHL) | Stock Overview & Key Data
Procter & Gamble Performance Comparison
Stock Range
Today's Range
Low: ₹6,208.00
High: ₹6,325.00
on September 15, 2025
52 Week Range
Low: ₹4,863.00
High: ₹6,739.00
on October 29, 2024
on August 29, 2025
All-Time High: ₹7,500.00 on February 8, 2021
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR105.3B
EPS
111.00
P/E Ratio (TTM)
57.14
Forward P/E
N/A
P/B Ratio
19.56
PEG Ratio
-4.58
Div. Yield
2.35%
ROE
37.41%
Beta
0.429
Debt to Equity
0.01
Financial Highlights
Profitability
Gross Margin
72.25%
Operating Margin
25.06%
Profit Margin
20.62%
Returns and Earnings
Return on Assets (TTM)
25.30%
Return on Equity (TTM)
37.41%
EBITDA
INR4.2B
Net Income (TTM)
INR2.5B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR733.79
Quarterly Revenue Growth (YoY)
19.30%
Quarterly Earnings Growth (YoY)
294.40%
Dividend Information
Last 12-Month Dividend
₹140.00
Current Dividend Yield
2.35%
3-Year Average Dividend Yield
0.99%
3-Year Average Annual Dividend
₹98.83
3-Year Total Dividends
₹296.50
Ex-Dividend Date
February 21, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Procter & Gamble PGHL | 105.29B Mid-cap | -1.23% | -0.34% | 7.39% | 18.39% | 20.48% | 13.77% | 53.12% | 20.14% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 0.56% | 4.66% | -1.86% | -3.66% | -13.43% | -14.34% | 71.30% | 219.01% |
| Divi's Laboratories DIVISLAB | 1.57T Large-cap | -4.58% | -6.29% | -16.72% | 2.89% | -5.98% | 5.24% | 52.85% | 79.00% |
| Alembic APLLTD | 182.09B Mid-cap | -1.73% | -4.07% | -10.65% | 0.83% | -13.79% | -27.24% | 46.45% | -5.63% |
| Jubilant Pharmova JUBLPHARMA | 171.19B Mid-cap | -0.50% | 3.66% | -10.84% | 17.71% | -0.05% | -2.93% | 210.44% | 101.03% |
| Neuland Laboratories NEULANDLAB | 198.78B Mid-cap | 2.42% | 14.83% | 29.53% | 33.98% | 7.64% | 27.40% | 938.16% | 1,120.48% |
Ownership & Short Interest
Insider Ownership
52.19%
Institutional Ownership
16.31%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
43K
Average 90-Day Volume
23K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PGHL's 52-week high and low?
- In the last 52 weeks, Procter & Gamble reached a high of ₹6,739.00 (on August 29, 2025) and a low of ₹4,863.00 (on October 29, 2024).
- What is the market cap and P/E ratio for PGHL?
- Curious about Procter & Gamble's size and valuation? Its market capitalization stands at 105.29B. When it comes to valuation, the P/E ratio (trailing twelve months) is 57.14, and the forward P/E (looking ahead) is N/A.
- Does PGHL pay dividends? If so, what's the yield?
- Yes, Procter & Gamble is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 2.35%, and the company has paid an average of ₹98.83 per share annually over the past 3 years.
- Who are Procter & Gamble's main competitors or similar companies to consider before investing?
When looking at Procter & Gamble, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -14.34% 71.30% Divi's Laboratories
DIVISLAB1.57T Healthcare Drug Manufacturers - Specialty & Generic 5.24% 52.85% Alembic
APLLTD182.09B Healthcare Drug Manufacturers - Specialty & Generic -27.24% 46.45% Jubilant Pharmova
JUBLPHARMA171.19B Healthcare Drug Manufacturers - Specialty & Generic -2.93% 210.44% Neuland Laboratories
NEULANDLAB198.78B Healthcare Drug Manufacturers - Specialty & Generic 27.40% 938.16% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Procter & Gamble Health Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Procter & Gamble's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 37.41%, the Debt to Equity ratio from the most recent quarter is 0.01, and its Gross Profit Margin stands at 72.25%.
- What is the recent revenue and earnings growth for PGHL?
- Looking at Procter & Gamble's growth, its revenue over the trailing twelve months (TTM) was INR12B. Compared to the same quarter last year (YoY), quarterly revenue grew by 19.30%, and quarterly earnings saw a YoY growth of 294.40%.
- How much of PGHL stock is held by insiders and institutions?
- Wondering who owns Procter & Gamble stock? Company insiders (like executives and directors) hold about 52.19% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 16.31%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.